ADVERUM BIOTECHNOLOGIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.17 USD | -1.40% |
|
-13.98% | +21.81% |
| May. 09 | Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 30 | HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target | MT |
Presenter SpeechMike Connor (Analysts)Good morning. My name is Mike Connor, and on behalf of t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.17
USD
Average target price
35.33
USD
Spread / Average Target
+285.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.81% | 193M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Transcript : Adverum Biotechnologies, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-13-2021 07